Short-term efficacy of adefovir dipivoxil as an add-on therapy in the pegylated IFNα-2a treatment for HBeAg positive chronic hepatitis B patients
10.3760/cma.j.issn.1003-9279.2010.01.014
- VernacularTitle:聚乙二醇干扰素α-2a加用阿德福韦酯治疗HBeAg阳性慢性乙肝的短期疗效观察
- Author:
Lu-Biao CHEN
1
;
Xin SHU
;
Yu-Sheng JIE
;
Xiao-An YANG
;
Ka ZHANG
;
Gang LI
;
Qi-Huan XU
Author Information
1. 中山大学附属第三医院
- Keywords:
Hepatitis B;
Interferon Alfa-2α;
Adefovir dipivoxil;
Hepatitis/Therapy
- From:
Chinese Journal of Experimental and Clinical Virology
2010;24(1):39-41
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate whether the combination therapy of pegylated IFNα-2a plus adefovir dipivoxil (ADV) improve the efficacy of the treatment in CHB patients with HBeAg positive or not. Methods 57 CHB patients with HBeAg positive received 48-week pegylated IFNα-2a therapy were enrolled into this study. If serum HBV DNA levels exceeded 1000 copies/ml at week 24, the patients were assigned to group A (pegylated IFN-α2a plus ADV, 21 cases) or group B (pegylated IFNα-2a only, 14 cases);otherwise, they received the unceasing monotherapy of pegylated IFNα-2a (group C, 22 cases). Results At week 48, HBeAg seroconversion rates were 23.8% , 28.6% and 63.6% (A vs C,P=0.014), but rates of aminotransferases normalization and HBV DNA suppression (< 1000 copies/ml) were not statistically significant among three groups. But during week 24 to week 48, rates of HBeAg seroconversion, aminotransferases normalization and HBV DNA suppression were also not statistically significant between group A and B. But amplitude of DNA drop in group A was much more than that in group B (2.60±1.37 vs 0.86±2.09, P=0.005). Conclusion An ADV add-on therapy in pegylated IFNα-2a treatment seems able to improve the inhibition of HBV DNA in chronic hepatitis B patients with HBeAg positive. It requires a large, double-blind, randomized clinical trial to further provent.
